Will Blood Substitutes Deliver?
This article was originally published in Start Up
Executive SummaryDevelopers of blood substitutes struggle to design clinical trials that show their products can reduce patients’ exposure to donated blood. But manufacturing and scale-up issues present tough challenges, especially for hemoglobin-based products. Newclinical procedures can help blood substitutes perform better, but will require significant physician education. Partnership may prove key in reaching a market analysts estimate at $2-$10 billion.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.